Neurogene Inc.

NASDAQ (USD): Neurogene Inc. (NGNE)

Last Price

20.30

Today's Change

+4.71 (30.21%)

Day's Change

15.48 - 20.93

Trading Volume

1,057,188

Profile
NGNE

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Rachel L. McMinn Ph.D. Dr. Rachel L. McMinn Ph.D.

Full Time Employees:  91 91

IPO Date:  2014-03-07 2014-03-07

CIK:  0001404644 0001404644

ISIN:  US64135M1053 US64135M1053

CUSIP:  64135M105 64135M105

Beta:  0.00 0.00

Last Dividend:  0.00 0.00

Dcf Diff:  10.01 10.01

Dcf:  10.29 10.29

Description

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Address

535 W 24th Street,
New York, NY 10011, US

(877) 237-5020

http://www.neurogene.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment